pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

423 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT814Endpoints614BioPharma Dive237onclive165Fierce Biotech81BioSpace79raps32globenewswire health26
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch
    New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.
    BioPharma Dive · 1mo ago↗ source
  • FDA Issues Emergency Use Authorization for Generic Over-the-Counter Drug to Treat New World Screwworm in Dogs and Cats
    FDA today issued an Emergency Use Authorization (EUA) for generic Nitenpyram Tablets (nitenpyram) for the treatment of New World screwworm (NWS) infestations (myiasis) in dogs, puppies, cats, and k…
    fda press · 1mo ago↗ source
  • Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
    The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.
← prev
page 6 of 17
next →
fda press21
fda recalls20
fda medwatch16
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
BioPharma Dive · 1mo ago↗ source
  • Ethyreal starts up with $101M and takes aim at a pair of immune diseases
    The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related condition, too.
    BioPharma Dive · 1mo ago↗ source
  • Sanofi stops immune drug trial in latest research setback
    The failure adds to a series of mixed or negative readouts and leaves in doubt the future of a therapy Sanofi has viewed as a potential blockbuster.
    BioPharma Dive · 1mo ago↗ source
  • Parabilis sets a record with a $670M biotech IPO
    The largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that’s now resulted in 12 drug startups securing more than $4.1 billion combined.
    BioPharma Dive · 1mo ago↗ source
  • AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine
    Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees and Cartesian boosted its ‘in vivo’ cell…
    BioPharma Dive · 1mo ago↗ source
  • Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
    Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.
    BioPharma Dive · 1mo ago↗ source
  • Stealthy startup Treeline plans a reverse merger
    Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.
    BioPharma Dive · 1mo ago↗ source
  • FDA Expands Sunscreen Options for the First Time in 20 Years
    Today, the U.S. Food and Drug Administration added bemotrizinol to the list of permitted sunscreen active ingredients, marking a significant milestone in the agency's efforts to advance sunscreen i…
    fda press · 1mo ago↗ source
  • GSK boosts cancer pipeline with $11B Nuvalent buyout
    The British drugmaker's third acquisition this year gives it two experimental lung cancer drugs under FDA review that it hopes will support a franchise.
    BioPharma Dive · 1mo ago↗ source
  • City banks nearly $100M for next-gen RNAi drugs
    Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon follow.
    BioPharma Dive · 1mo ago↗ source
  • Roche stakes $700M on Nurix’s protein-degrading drug
    Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove superior to existing medicines that block its activity.
    BioPharma Dive · 1mo ago↗ source
  • Tango data add to growing momentum for pancreatic cancer drugs
    A combination involving Tango’s experimental therapy appeared to boost response rates in a small clinical trial well beyond what would be expected, sparking a share surge.
    BioPharma Dive · 1mo ago↗ source
  • Incyte to buy blood disorder drug in possibly $2B deal
    Acquiring Vega Therapeutics, an offshoot of "hub-and-spoke" biotech Star Therapeutics, would give Incyte a medicine that’s in late-stage testing and designed to control bleeding.
    BioPharma Dive · 1mo ago↗ source
  • J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1B
    The buyout hands J&J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.
    BioPharma Dive · 1mo ago↗ source
  • ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option
    At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.
    BioPharma Dive · 1mo ago↗ source
  • Innovation alone is no longer enough in biopharma
    In biopharma, the next edge may come from the systems that turn discovery into scale.
    BioPharma Dive · 1mo ago↗ source
  • Precision under pressure: Logistic solutions for nuclear medicine scalability
    Racing the clock: How precision logistics deliver life-saving nuclear medicine.
    BioPharma Dive · 1mo ago↗ source
  • Study data convince Lundbeck to push new migraine drug forward
    A possible alternative to “anti-CGRP” medications, the drug didn’t meet some analysts’ expectations in mid-stage testing but still convinced Lundbeck to pursue further development.
    BioPharma Dive · 1mo ago↗ source
  • Generic drugmakers gain key victory in ‘skinny label’ patent case
    The Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching implications for the availability of generics.
    BioPharma Dive · 1mo ago↗ source
  • Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
    While many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet.
    BioPharma Dive · 1mo ago↗ source
  • Alnylam, Inceptive ink AI deal potentially worth $2B
    The RNA-focused drugmaker says Inceptive's tools will help prioritize the best development options as well as speed up the research process.
    BioPharma Dive · 1mo ago↗ source
  • An ADC specialist sinks on safety concerns for blood cancer drug
    Shares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes “may be difficult to accept for physicians, patients and regulators.”
    BioPharma Dive · 1mo ago↗ source
  • Otsuka showcases kidney drug data; Pfizer cuts an AI deal
    Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s alliance with Innovent paid early dividends and Axsome warded off gen…
    BioPharma Dive · 1mo ago↗ source